Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Non-Responder Patients With Chronic Hepatitis C (CHC)

Status: Completed

Protocol number: ML16788

Sponsor: Roche SAS

Company division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of PEGASYS compared with daily vitamin E on fibrosis progression in patients with chronic hepatitis viral infection nonresponsive to pegylated interferon plus ribavirin

Brief summary: This study will evaluate the efficacy and safety of PEGASYS compared with that of daily vitamin E in patients with CHC who are non-responders to CHC treatments. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals. Target sample size is 200.

Study phase: IV

Study type: Interventional; Treatment; Non-Randomized; Open Label; Uncontrolled; Parallel; Safety/Efficacy study

Condition: Hepatitis C, Chronic

Intervention type: Drug

Intervention name: peginterferon alfa-2a (40KD)[PEGASYS]

Primary outcome: 1. Efficacy: Improvement of 1 point on fibrosis score or stabilization on hepatic biopsy at Week 96 (Metavir) or 2 points (Ishak score)

Key secondary outcomes: 1. Efficacy: Virologic and biochemical response, fibrosis markers dosage Safety: Adverse events, hemoglobin, other laboratory tests

Inclusion criteria:

  • adult patients 18-74 years of age;
  • CHC infection;
  • not responsive to previous therapy with pegylated interferon + ribavirin;
  • chronic liver disease consistent with CHC infection;
  • compensated liver disease.

Exclusion criteria:

  • women who are pregnant or breastfeeding;
  • systemic anti-viral, anti-neoplastic, or immunomodulatory agent <=6 months before study;
  • conditions associated with chronic liver disease;
  • human immunodeficiency virus (HIV) infection.

Gender: Males or Females

Age limits: Min: 18 Years Max: 74 Years

Accepts healthy volunteers: No

Trial registration date: 08/25/2005

Date last updated: 9/29/2008


Link to trial result

This trial was conducted at the following locations:

France

  • Amiens
  • Annecy
  • Argenteuil
  • Caen
  • Chambray-Lès-Tours
  • Clichy
  • Corbeil-Essonnes
  • Creteil
  • Grenoble
  • Hyeres
  • Lomme
  • Marseille
  • Metz
  • Nanterre
  • Nice
  • Paris
  • Poitiers
  • Rouen
  • Saint Laurent Du Var
  • St Dizier
  • Strasbourg
  • Toulouse
  • Vandoeuvre-Les-Nancy

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply